Ritlecitinib is in clinical development for the treatment of patients with alopecia areata (AA). AA is a disease that develops when the body attacks its own hair follicles (where the hair grows from), which can cause hair loss as small round patches of baldness anywhere on the body. Most commonly, this occurs on the scalp and has high rates of recurrence. There are also psychological implications such as increased levels of anxiety and depression in people with AA.
Ritlecitinib is an inhibitor of proteins called janus kinases (JAKs) and is administered orally. JAKs play a major role in signalling for hair follicle growth, specifically JAK inhibitors impede the immune system (the body’s defence against germs), including pathways involved in antiviral immunity, which appear to be active in AA. If licensed, ritlecitinib would offer an additional treatment option for those with AA.
When blood sugar levels are high or fluctuate regularly, as in people with diabetes, skin that would normally heal may not properly repair itself because of nerve damage. As a result, even a mild injury can start a foot ulcer. Granexin gel contains the peptide ACT1, which possesses potential anti-inflammatory and regenerative properties when administered topically to diabetic foot ulcers. If licensed, granexin gel may offer an additional therapy option for diabetic foot ulcers which are a particularly difficult-to-treat chronic wound type.